Haemonetics (HAE) Non-Current Deferred Tax Liability (2010 - 2026)

Haemonetics' Non-Current Deferred Tax Liability history runs 17 years deep, the most recent figure standing at $38.0 million for Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 72.81% year-over-year to $38.0 million in Q1 2026; TTM through Mar 2026 was $38.0 million, a 72.81% decrease from a year earlier, with the FY2026 full-year figure at $38.0 million, down 72.81% from the prior year.
• Non-Current Deferred Tax Liability eased to $38.0 million in Q1 2026 per HAE's latest filing, from $56.0 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $140.0 million in Q1 2025 and bottomed at $26.1 million in Q1 2022.
• The 5-year median for Non-Current Deferred Tax Liability is $48.1 million (2022), against an average of $52.1 million.
• Across the five-year window, Non-Current Deferred Tax Liability surged 166.57% in 2022 and plunged 72.81% in 2026, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $40.2 million in 2022, then jumped by 55.03% to $62.2 million in 2023, then retreated by 1.28% to $61.5 million in 2024, then retreated by 8.9% to $56.0 million in 2025, then plunged by 32.03% to $38.0 million in 2026.
• Per Business Quant, the three latest HAE Non-Current Deferred Tax Liability figures stand at $38.0 million (Q1 2026), $56.0 million (Q4 2025), and $58.2 million (Q3 2025).